Cost-effectiveness of Obinutuzumab Plus Bendamustine in Chinese Patients with Relapse and Refractory Follicular Lymphoma

Overview

Journal J Comp Eff Res

Specialty Health Services

Date 2023 Nov 2

PMID 37916709

Authors

Jun Ma

Donglu Zhao

Bihong Zhen

Yan Xia

Qianyi Gong

Wendong Chen

Affiliations

Soon will be listed here.

Abstract

A decision analytic model was constructed to assess the cost-effectiveness of obinutuzumab plus bendamustine followed by obinutuzumab maintenance therapy (O-B-O) in Chinese patients with relapsed and refractory follicular lymphoma (rrFL). O-B-O was associated with a dominant or more favorable cost-effectiveness than the conventional therapies. Survival outcomes, quality of life of progression-free survival, and subsequent treatment costs for progressive disease were the main drivers of the cost-effectiveness of O-B-O. The cost-effectiveness proportions of O-B-O relative to conventional therapies under the recommended cost-effectiveness threshold ranged from 61.0% to 99.9%. Thus, O-B-O was highly cost-effective for treating patients with rrFL in China compared with conventional therapies.

Citing Articles

Is first-line treatment with polatuzumab vedotin-rituximab-cyclophosphamide, doxorubicin and prednisone (pola-R-CHP) for previously untreated diffuse large B-cell lymphoma cost-effective in China? A cost-effectiveness analysis using a Markov model.

Dong L, Zhong W, Chen T, Zhao Q, Liu W, Qiu X BMJ Open. 2025; 15(1):e086251.

PMID: 39832983 PMC: 11751847. DOI: 10.1136/bmjopen-2024-086251.

Efficacy, safety and cost-effectiveness of obinutuzumab in patients with follicular lymphoma: a rapid review.

Wang C, Dong Y, Men P, Zhang R, Xiao Y, Bu Y Front Pharmacol. 2025; 15():1426772.

PMID: 39830356 PMC: 11738910. DOI: 10.3389/fphar.2024.1426772.

References

Link B . Transformation of follicular lymphoma - Why does it happen and can it be prevented?. Best Pract Res Clin Haematol. 2018; 31(1):49-56. DOI: 10.1016/j.beha.2017.10.005. View

Hainsworth J, Greco F, Raefsky E, Thompson D, Lunin S, Reeves Jr J . Rituximab with or without bevacizumab for the treatment of patients with relapsed follicular lymphoma. Clin Lymphoma Myeloma Leuk. 2014; 14(4):277-83. DOI: 10.1016/j.clml.2014.02.010. View

Haukaas F, Ohna A, Krivasi T . Cost-Effectiveness of Obinutuzumab in Combination with Bendamustine Followed by Obinutuzumab Maintenance versus Bendamustine Alone in Treatment of Patients with Rituximab-Refractory Follicular Lymphoma in Norway. Appl Health Econ Health Policy. 2018; 16(4):569-577. DOI: 10.1007/s40258-018-0401-y. View

Leonard J, Jung S, Johnson J, Pitcher B, Bartlett N, Blum K . Randomized Trial of Lenalidomide Alone Versus Lenalidomide Plus Rituximab in Patients With Recurrent Follicular Lymphoma: CALGB 50401 (Alliance). J Clin Oncol. 2015; 33(31):3635-40. PMC: 4622102. DOI: 10.1200/JCO.2014.59.9258. View

Matsumoto K, Takayama N, Aisa Y, Ueno H, Hagihara M, Watanabe K . A phase II study of bendamustine plus rituximab in Japanese patients with relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma previously treated with rituximab: BRB study. Int J Hematol. 2015; 101(6):554-62. DOI: 10.1007/s12185-015-1767-3. View

Davies A, Kater A, Sharman J, Stilgenbauer S, Vitolo U, Klein C . Obinutuzumab in the treatment of B-cell malignancies: a comprehensive review. Future Oncol. 2022; 18(26):2943-2966. PMC: 11284610. DOI: 10.2217/fon-2022-0112. View

Muntanola A, Mozas P, Mercadal S, Huguet M, Bobillo S, Bastos-Oreiro M . Early progression in follicular lymphoma in the absence of histological transformation or high-risk Follicular Lymphoma International Prognostic Index still has a favourable outcome. Br J Haematol. 2022; 200(3):306-314. DOI: 10.1111/bjh.18522. View

Zinzani P, Khuageva N, Wang H, Garicochea B, Walewski J, Van Hoof A . Bortezomib plus rituximab versus rituximab in patients with high-risk, relapsed, rituximab-naïve or rituximab-sensitive follicular lymphoma: subgroup analysis of a randomized phase 3 trial. J Hematol Oncol. 2012; 5:67. PMC: 3502148. DOI: 10.1186/1756-8722-5-67. View

Alduaij W, Ivanov A, Honeychurch J, Cheadle E, Potluri S, Lim S . Novel type II anti-CD20 monoclonal antibody (GA101) evokes homotypic adhesion and actin-dependent, lysosome-mediated cell death in B-cell malignancies. Blood. 2011; 117(17):4519-29. PMC: 3099571. DOI: 10.1182/blood-2010-07-296913. View

10.

van Oers M, Van Glabbeke M, Giurgea L, Klasa R, Marcus R, Wolf M . Rituximab maintenance treatment of relapsed/resistant follicular non-Hodgkin's lymphoma: long-term outcome of the EORTC 20981 phase III randomized intergroup study. J Clin Oncol. 2010; 28(17):2853-8. PMC: 2903319. DOI: 10.1200/JCO.2009.26.5827. View

11.

Johnson P, Rohatiner A, Whelan J, Price C, Love S, Lim J . Patterns of survival in patients with recurrent follicular lymphoma: a 20-year study from a single center. J Clin Oncol. 1995; 13(1):140-7. DOI: 10.1200/JCO.1995.13.1.140. View

12.

Bachy E, Seymour J, Feugier P, Offner F, Lopez-Guillermo A, Belada D . Sustained Progression-Free Survival Benefit of Rituximab Maintenance in Patients With Follicular Lymphoma: Long-Term Results of the PRIMA Study. J Clin Oncol. 2019; 37(31):2815-2824. PMC: 6823890. DOI: 10.1200/JCO.19.01073. View

13.

Muntanola A, Baumann T, Caballero A, Sanchez-Gonzalez B, Mercadal S, Escoda L . Results of R-ESHAP as salvage therapy in refractory/relapsed follicular lymphoma: a real-world experience on behalf of GELCAB group. Ann Hematol. 2020; 99(7):1627-1634. DOI: 10.1007/s00277-020-04101-7. View

14.

Kuruvilla J, Ewara E, Elia-Pacitti J, Ng R, Eberg M, Kukaswadia A . Estimating the Burden of Illness of Relapsed Follicular Lymphoma and Marginal Zone Lymphoma in Ontario, Canada. Curr Oncol. 2023; 30(5):4663-4676. PMC: 10216939. DOI: 10.3390/curroncol30050352. View